Ipragliflozin L-Proline

伊格列净L-脯氨酸盐

Report date: 2022/09/07 14:54:42
NME

Base Information

Drug NameIpragliflozin L-Proline
Drug Alias Name依格列净IpragliflozineIpragliflozinumIpragliflozinaipragliflozin +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[4] 
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2014/01/17
Country/TerritoryCzechiaUnited StatesSlovakia +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesKotobukiAstellas Pharma Inc
Inactive CompaniesAstellas Pharma Taiwan IncAstellas Pharma Europe BvAstellas Pharma Global Development Inc
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsLiver Diseases

Other Information

ATC CodeA10BK05
Related LinksKEGG